Track topics on Twitter Track topics that are important to you
TORONTO, ON--(Marketwired - August 07, 2015) - Join featured speakers James Mapes, Chief Scientific Officer at Myriad RBM, and Mark Roskey, VP/GM of Applications and Reagents at Quanterix, for a one-hour live session on Tuesday, August 25, 2015 at 11am EDT (4pm BST/ GMT +1).
Reliably detecting immune-modulating proteins in serum and plasma from normal individuals has historically been impossible due to the lack of sensitivity of conventional immunoassays. Quanterix and Myriad RBM are working together to change this paradigm via ultrasensitive, high quality immunoassay services that offer drug developers an unparalleled approach to clinical research.
Quanterix, the developer of single molecule arrays (Simoa) technology, will describe the use of Simoa for the detection of proteins at very low concentrations, capable of providing a 1000-fold improvement in sensitivity to proteins over conventional assays. We will review the scientific principles that allow counting individual protein molecules and we will demonstrate how the Simoa technology can be used to obtain remarkable improvements in sensitivity, which has enabled significant breakthroughs in several therapy areas.
Myriad RBM, a leader in immunoassay testing services, will describe validated Simoa-based assay services and how carefully designed calibrators and controls ensure quality, precision and accuracy. Examples of how these reproducible assays, offered as a service in Myriad RBM's CLIA certified lab, can measure proteins at the femtogram per mL level will be demonstrated by quantifying key immune modulating proteins, present at undetectable levels with conventional technology in serum and plasma, from normal and diseased subjects. In conclusion, we will show that the unprecedented sensitivity and reliability of these ultrasensitive immunoassay services have the potential to revolutionize clinical research in multiple therapeutic areas including immuno-oncology, autoimmune disorders, cardiovascular diseases and other research focusing on inflammatory processes.
To learn more about this event visit: Development & Validation of Ultrasensitive Simoa-based Immunoassay Services
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Image Available: http://www.marketwire.com/library/MwGo/2015/8/7/11G050013/Images/myriadrbm_500_edit-1131344754463.jpg Image Available: http://www.marketwire.com/library/MwGo/2015/8/7/11G050013/Images/Quanterix_Logo_350-1032175861865.jpgContact: Dian Razak Tel: +1 (416) 977-6555 ext 352 Email: NEXT ARTICLE
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...
Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...